Rösch AG Medizintechnik
Rösch AG Medizintechnik english

Approval of syringe without a needle -INJEX- as combination with growth hormone Corporate-news announcement sent by DGAP. The sender is solely responsible for the contents of this announcement. ——————————————————————————– Approval of syringe without a needle -INJEX- as combination with growth hormone Rösch AG Medizintechnik (WKN 529140) today announced its needle-free delivery device, INJEX(TM), has received approval for a type II variation to be used as a delivery system for the administration of Genotropin(R) (somatropin rDNA origin injection). This variation was carried out using the European Union Mutual Recognition procedure and the approval will apply to all EU member states where Genotropin is registered, once national documentation is finalised in each country. ‘This is the first time that a pharmaceutical product has been licenced to be used with our INJEX(TM) system, which we take as a confirmation of the value and innovation of our new delivery technology’ said Prof. Weidler, CEO of Rösch AG. ‘This approval – relevant for the EU – will clearly facilitate our negotiations with pharma companies for cooperations.’ Rösch AG announced the signing of a worldwide exclusive contract with Pharmacia AB, Stockholm, in January 2001. Pharmacia was granted exclusive rights to the INJEXTM needle free delivery system developed by Rösch AG for use with its growth hormones Genotropin(R). The five-year contract will run until 2006 with the option of renewal for a further 2 years. Pharmacia is a world leader in endocrine care and has been actively involved in developing clinical applications for growth hormone for more than 30 years. Available in more than 50 countries, Genotropin is the leading brand of growth hormones in the world. Genotropin is approved for the long-term treatment of children and adults with growth hormone deficiency (GHD), for children suffering from growth failure due to Prader-Willi syndrome, chronic renal insufficiency and Turner syndrome, and for children born small for gestational age (not all indications are licensed in all countries). Genotropin is available by prescription only. Executive Board Further information: Rösch AG Medizintechnik Investor Relations Buckower Damm 114 Tel.: 030-667915-0 Fax: 030-667915-66 e-mail: vorstand@roesch-ag.de end of message, (c)DGAP 06.06.2002